Clinical trials: Epithelial Cancer Patients
Fallopian Tubes Cancer, Ovarian Cancer
Polyvalent Vaccine-KLH Conjugate + Opt-821 Given in Combination With Bevacizumab
The immune system of the body has the ability to fight and eliminate infections and cancers. Immune treatments, such as in this study, seek to teach the immune system to find and destroy cancer cells.
- Conditions
- Fallopian Tubes Cancer, Ovarian Cancer, Peritoneal Cancer
- Trial name
- NCT01223235
- Testing
- bevacizumab and the polyvalent vaccine-KLH conjugate + OPT-821
- Where
- United States
- Volunteers
- 22 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Advanced Pancreatic Neuroendocrine Tumor, Locally Advanced Pancreatic Neuroendocrine Tumor
Everolimus and Octreotide Acetate With or Without Bevacizumab in Treating Patients With Locally Advanced or Metastatic Pancreatic Neuroendocrine Tumors That Cannot Be Removed by Surgery
This randomized phase II trial studies how well everolimus and octreotide acetate with or without bevacizumab works in treating patients with pancreatic neuroendocrine tumors that cannot be removed by surgery and have spread…
- Conditions
- Advanced Pancreatic Neuroendocrine Tumor, Locally Advanced Pancreatic Neuroendocrine Tumor, Pancreatic Gastrinoma, Pancreatic Neuroendocrine Tumor G1
- Trial name
- NCT01229943
- Testing
- Bevacizumab, Everolimus, Octreotide Acetate
- Where
- 394 sites in United States, Canada
- Volunteers
- 150 people
- Sponsor
- National Cancer Institute (NCI)
Liver Cancer, Hepatic Tumors
Follow-up Yttrium-90 Internal Pair Production PET/CT vs Brehmsstrahlung Imaging in Patients With Primary/Metastatic Liver Tumors
This is a prospective non-blinded case series involving the acquisition of a pair production PET/CT as soon as possible after an already performed Y-90 Sirspheres treatment of hepatic malignancy.
- Trial name
- NCT02202317
- Testing
- PET/CT Scan
- Where
- United States
- Volunteers
- 9 people
- Sponsor
- University of Miami
Glioblastoma
Cilengitide, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma and Unmethylated Gene Promoter Status
CORE is a Phase 2 clinical trial in newly diagnosed glioblastoma in subjects with an unmethylated O6-methylguanine-deoxyribonucleic acid methyltransferase (MGMT) gene promoter in the tumor tissue.
- Trial name
- CORE (NCT00813943)
- Testing
- Cilengitide (2-times weekly), cilengitide (5-times weekly), Temozolomide
- Where
- 2 sites in United States, Germany
- Volunteers
- 265 people
- Sponsor
- EMD Serono
Intractable Epilepsy, Malignant Glioma
Perampanel for the Reduction of Seizure Frequency in Patients With High-grade Glioma and Focal Epilepsy
This phase IV trial studies the side effects and how well perampanel works in reducing seizure frequency in patients with high-grade glioma and focal epilepsy. Perampanel is a drug used to treat seizures.
- Conditions
- Intractable Epilepsy, Malignant Glioma, Seizure Disorder, WHO Grade 2 Glioma
- Trial name
- NCT04650204
- Testing
- Anticonvulsant Agent, Perampanel, Quality-of-Life Assessment
- Where
- United States
- Volunteers
- 4 people
- Sponsor
- Mayo Clinic
Cancer
Aprepitant in Preventing Nausea and Vomiting in Patients Who Are Undergoing a Stem Cell Transplant
RATIONALE: Antiemetic drugs, such as aprepitant, ondansetron, and dexamethasone, may help lessen or prevent nausea and vomiting in patients undergoing a stem cell transplant.
- Trial name
- NCT00248547
- Testing
- aprepitant, dexamethasone, ondansetron
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- OHSU Knight Cancer Institute
Thyroid Gland Anaplastic Carcinoma
Intensity-Modulated Radiation Therapy and Paclitaxel With or Without Pazopanib Hydrochloride in Treating Patients With Anaplastic Thyroid Cancer
This randomized phase II trial studies the side effects and how well intensity-modulated radiation therapy (IMRT) and paclitaxel with or without pazopanib hydrochloride works in treating patients with anaplastic thyroid cancer.
- Trial name
- NCT01236547
- Testing
- Intensity-Modulated Radiation Therapy, Paclitaxel, Pazopanib Hydrochloride
- Where
- 130 sites in United States
- Volunteers
- 123 people
- Sponsor
- National Cancer Institute (NCI)
Fallopian Tube Clear Cell Adenocarcinoma, Fallopian Tube Endometrioid Adenocarcinoma
Carboplatin and Paclitaxel With or Without Bevacizumab in Treating Patients With Stage III or Stage IV Ovarian Epithelial, Primary Peritoneal, or Fallopian Tube Cancer
This randomized phase III trial studies carboplatin, paclitaxel, and bevacizumab to see how well they work compared to carboplatin, paclitaxel, and placebo in treating patients with stage III or stage IV ovarian epithelial…
- Conditions
- Fallopian Tube Clear Cell Adenocarcinoma, Fallopian Tube Endometrioid Adenocarcinoma, Fallopian Tube Mucinous Adenocarcinoma, Fallopian Tube Serous Adenocarcinoma
- Trial name
- NCT00262847
- Testing
- Bevacizumab, Carboplatin, Laboratory Biomarker Analysis
- Where
- 632 sites in United States, Canada and 2 more
- Volunteers
- 1,873 people
- Sponsor
- National Cancer Institute (NCI)
Leukemia, Lung Cancer
Vaccine Therapy and GM-CSF in Treating Patients With Acute Myeloid Leukemia, Myelodysplastic Syndromes, Non-Small Cell Lung Cancer, or Mesothelioma
RATIONALE: Vaccines made from peptides may help the body build an effective immune response to kill cancer cells. Biological therapies, such as GM-CSF, may stimulate the immune system in different ways and stop cancer cells from…
- Conditions
- Leukemia, Lung Cancer, Malignant Mesothelioma, Myelodysplastic Syndromes
- Trial name
- NCT00398138
- Testing
- WT-1 analog peptide vaccine, incomplete Freund's adjuvant, sargramostim
- Where
- United States
- Volunteers
- 22 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Nasopharyngeal Nonkeratinizing Carcinoma, Recurrent Nasopharynx Carcinoma
Nivolumab in Treating Patients With Recurrent and/or Metastatic Nasopharyngeal Cancer
This phase II trial studies how well nivolumab works in treating patients with nasopharyngeal cancer that has returned after a period of improvement (recurrent) and/or has spread to other parts of the body (metastatic).
- Conditions
- Nasopharyngeal Nonkeratinizing Carcinoma, Recurrent Nasopharynx Carcinoma, Stage III Nasopharyngeal Carcinoma AJCC v7, Stage IV Nasopharyngeal Carcinoma AJCC v7
- Trial name
- NCT02339558
- Testing
- Laboratory Biomarker Analysis, Nivolumab
- Where
- 19 sites in United States, China and 1 more
- Volunteers
- 45 people
- Sponsor
- National Cancer Institute (NCI)
Breast Cancer
Combination Chemotherapy With or Without Trastuzumab in Treating Patients With Stage II or Stage III Breast Cancer
RATIONALE: Drugs used in chemotherapy work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00295893
- Testing
- cyclophosphamide, docetaxel, doxorubicin hydrochloride
- Where
- United States
- Volunteers
- 121 people
- Sponsor
- City of Hope Medical Center
Carcinoma, Non-Small-Cell Lung, Adenocarcinoma
BIBW 2992 (Afatinib) vs Gemcitabine-cisplatin in 1st Line Non-small Cell Lung Cancer (NSCLC)
To investigate the efficacy and safety of BIBW 2992 compared to standard first-line chemotherapy in patients with stage IIIB or IV adenocarcinoma of the lung harbouring an EGFR activating mutation
- Trial name
- NCT01121393
- Testing
- Gemcitabine+Cisplatin, BIBW 2992
- Where
- 36 sites in China, South Korea and 1 more
- Volunteers
- 364 people
- Sponsor
- Boehringer Ingelheim
Clear Cell Renal Cell Carcinoma, Stage I Renal Cell Cancer AJCC v6 and v7
Sunitinib Malate or Sorafenib Tosylate in Treating Patients With Kidney Cancer That Was Removed By Surgery
This randomized phase III trial studies sunitinib malate to see how well it works compared to sorafenib tosylate or placebo in treating patients with kidney cancer that has been removed by surgery.
- Conditions
- Clear Cell Renal Cell Carcinoma, Stage I Renal Cell Cancer AJCC v6 and v7, Stage II Renal Cell Cancer AJCC v7, Stage III Renal Cell Cancer AJCC v7
- Trial name
- ASSURE (NCT00326898)
- Testing
- Laboratory Biomarker Analysis, Quality-of-Life Assessment, Sorafenib Tosylate
- Where
- 987 sites in United States, Canada and 1 more
- Volunteers
- 1,943 people
- Sponsor
- National Cancer Institute (NCI)
Cutaneous Squamous Cell Carcinoma, Basal Cell Carcinoma
IFx-Hu2.0 for the Treatment of Patients With Skin Cancer
One hundred patients will receive IFx-Hu2.0 on an outpatient basis at a single time point in a single lesion. These patients will be assessed for any immediate adverse reactions and at Week 4 (Day 28+/-5 days) for any delayed…
- Trial name
- NCT04925713
- Testing
- IFx-Hu2.0
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- TuHURA Biosciences, Inc.
Adult Giant Cell Glioblastoma, Adult Glioblastoma
Bevacizumab With or Without Radiation Therapy in Treating Patients With Recurrent Glioblastoma
This randomized phase II trial studies how well bevacizumab with or without radiation therapy works in treating patients with recurrent glioblastoma.
- Conditions
- Adult Giant Cell Glioblastoma, Adult Glioblastoma, Adult Gliosarcoma, Recurrent Adult Brain Tumor
- Trial name
- NCT01730950
- Testing
- bevacizumab, radiation therapy
- Where
- 31 sites in United States
- Volunteers
- 182 people
- Sponsor
- Radiation Therapy Oncology Group
Metastatic Renal Cell Carcinoma
RAD001 Plus Best Supportive Care (BSC) Versus BSC Plus Placebo in Patients With Metastatic Carcinoma of the Kidney Which Has Progressed After Treatment With Sorafenib and/or Sunitinib
To assess whether daily treatment with RAD001 could slow the growth and spread of metastatic carcinoma of the kidney. The safety of RAD001 was also to be studied in this trial.
- Trial name
- RECORD-1 (NCT00410124)
- Testing
- RAD001
- Where
- 93 sites in United States, Australia and 8 more
- Volunteers
- 416 people
- Sponsor
- Novartis Pharmaceuticals
Clear Cell Renal Cell Carcinoma, Recurrent Renal Cell Carcinoma
Bevacizumab With or Without TRC105 in Treating Patients With Metastatic Kidney Cancer
This randomized phase II trial studies how well bevacizumab with or without anti-endoglin monoclonal antibody TRC105 (TRC105) works in treating patients with kidney cancer that has spread to other parts of the body (metastatic).
- Conditions
- Clear Cell Renal Cell Carcinoma, Recurrent Renal Cell Carcinoma, Stage IV Renal Cell Cancer, Type 1 Papillary Renal Cell Carcinoma
- Trial name
- NCT01727089
- Testing
- Anti-Endoglin Chimeric Monoclonal Antibody TRC105, Bevacizumab, Laboratory Biomarker Analysis
- Where
- 30 sites in United States, Australia and 1 more
- Volunteers
- 59 people
- Sponsor
- National Cancer Institute (NCI)
Ductal Breast Carcinoma in Situ, Lobular Breast Carcinoma in Situ
Hormone Therapy Or Chemotherapy Before Surgery Based on Gene Expression Analysis in Treating Patients With Breast Cancer
This randomized pilot clinical trial studied whether the Oncotype DX gene expression "Recurrence Score" (RS) would be useful for helping make a decision about which type of pre-operative treatment, hormone therapy or chemotherapy…
- Conditions
- Ductal Breast Carcinoma in Situ, Lobular Breast Carcinoma in Situ, Stage II Breast Cancer, Stage IIA Breast Cancer
- Trial name
- NCT01293032
- Testing
- Neoadjuvant Therapy, Therapeutic Conventional Surgery, Laboratory Biomarker Analysis
- Where
- 8 sites in United States, Canada
- Volunteers
- 59 people
- Sponsor
- Virginia Commonwealth University
Non-Small Cell Lung Cancer, Malignant Melanoma
Phase Ib of L-NMMA and Pembrolizumab
The purpose of this Phase Ib study is to test the safety of NG-monomethyl-L-arginine (L-NMMA) and pembrolizumab when used together in participants with melanoma, non-small cell lung cancer (NSCLC), head and neck squamous cell…
- Conditions
- Non-Small Cell Lung Cancer, Malignant Melanoma, Head and Neck Squamous Cell Carcinoma, Classical Hodgkin Lymphoma
- Trial name
- NCT03236935
- Testing
- L-NMMA, Pembrolizumab
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- The Methodist Hospital Research Institute
Human Papilloma Virus, Squamous Cell Carcinoma
De-Escalation Therapy for Human Papillomavirus Negative Disease
This study is looking to see if nivolumab, an immunotherapy drug, given with carboplatin and paclitaxel (2 chemotherapy agents) during induction therapy in advanced stage HPV negative patients can significantly shrink the…
- Conditions
- Human Papilloma Virus, Squamous Cell Carcinoma, Squamous Cell Carcinoma of the Head and Neck, HPV-Related Squamous Cell Carcinoma
- Trial name
- DEPEND (NCT03944915)
- Testing
- Carboplatin, Paclitaxel, Nivolumab
- Where
- United States
- Volunteers
- 35 people
- Sponsor
- University of Chicago
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.